Arcturus Therapeutics Advances mRNA Pipeline with Multiple Phase 2 Rare Disease Programs and Self-Amplifying RNA Vaccine Platform
核心洞察
Arcturus Therapeutics is advancing ARCT-032 (LUNAR-CF), a Phase 2 mRNA therapeutic candidate for cystic fibrosis (搜索), and ARCT-810 (LUNAR-OTC), a Phase 2 candidate for ornithine transcarbamylase deficiency (搜索).
The company's proprietary STARR self-amplifying mRNA technology and LUNAR lipid-mediated delivery system underpin its pipeline of liver and respiratory rare disease therapeutics.
KOSTAIVE, a self-amplifying RNA vaccine for COVID-19 (搜索), along with Phase 1 influenza vaccine candidates ARCT-2138 and ARCT-2304, highlight the company's infectious disease portfolio.
Arcturus Therapeutics Holdings Inc. (搜索), a San Diego-based messenger RNA medicines company founded in 2013, is advancing a diversified pipeline of mRNA therapeutics and vaccines targeting rare liver and respiratory diseases, as well as infectious diseases. The company's proprietary technology platforms — STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system — form the foundation of its development programs spanning from Phase 1 through Phase 2 clinical trials.
Rare Disease Pipeline: Two Phase 2 Programs in Development
Arcturus is currently advancing two mRNA therapeutic candidates in Phase 2 clinical development. ARCT-032, also designated as LUNAR-CF, is an mRNA therapeutic candidate being developed for cystic fibrosis (搜索), a genetic disorder affecting the respiratory and digestive systems. Concurrently, ARCT-810 (LUNAR-OTC) is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency, a rare urea cycle disorder that leads to ammonia accumulation in the blood.
Both programs leverage the company's LUNAR lipid-mediated delivery system, designed to enable efficient delivery of mRNA therapeutics to target tissues. The advancement of these candidates into mid-stage clinical trials represents a significant milestone for the company's rare disease strategy.
Infectious Disease Portfolio: Self-Amplifying RNA Vaccines
On the infectious disease front, Arcturus has developed KOSTAIVE, a self-amplifying RNA vaccine targeting COVID-19 (搜索). The company is also expanding its vaccine pipeline with two influenza candidates: ARCT-2138 (LUNAR-FLU), currently in a Phase 1 clinical trial for seasonal influenza (搜索), and ARCT-2304 (LUNAR-H5N1), also in a Phase 1 clinical trial for pandemic influenza (搜索).
The self-amplifying RNA platform, STARR, distinguishes Arcturus' approach by enabling the mRNA to replicate itself within host cells, potentially allowing for lower dosing and more durable protein expression compared to conventional mRNA vaccines.
Financial and Market Context
As of mid-2026, Arcturus Therapeutics' stock (NASDAQ: ARCT) has experienced considerable volatility. Over the prior year, the stock traded as high as $24.17 and as low as $5.50. Year-to-date performance through June 2026 showed a gain of 16.48%, though the stock subsequently declined, with July 2026 showing a month-to-date decline of 15.18%.
Analyst sentiment has trended negative, with one analyst downgrading the stock in the period leading up to June 2026 and another downgrade recorded through late July 2026, with no upgrades during either period. The company's trailing earnings per share remain negative, resulting in no meaningful price-to-earnings ratio. AAII's Value Grade rated the stock as "Expensive" (Grade D) in June, later shifting to "Average" (Grade C) in July. Momentum scores have been weak to very weak, with a weighted four-quarter relative price strength of -25.80% as of late July 2026.
With approximately 28.42 million shares outstanding, Arcturus continues to trade based largely on the perceived potential of its clinical pipeline rather than current financial performance, a common profile for clinical-stage biotechnology companies.